Novel 1,3,4‐oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation

Author:

Alsaad Hiba N.1ORCID,AL‐Jasani Baan M.2,Mahmood Ammar A. Razzak3,Tahtamouni Lubna H.45,Saleh Khaled M.6ORCID,AlSakhen Mai F.4,Kanaan Sana I.4,Yasin Salem R.4

Affiliation:

1. Department of Pharmaceutical Chemistry, College of Pharmacy University of Basrah Basrah Iraq

2. Department of Pharmacology and Toxicology, College of Pharmacy University of Basrah Basrah Iraq

3. Department of Pharmaceutical Chemistry, College of Pharmacy University of Baghdad Baghdad Iraq

4. Department of Biology and Biotechnology, Faculty of Science The Hashemite University Zarqa Jordan

5. Department of Biochemistry and Molecular Biology, College of Natural Sciences Colorado State University Fort Collins Colorado USA

6. Department of Basic Dental Sciences, Faculty of Dentistry The Hashemite University Zarqa Jordan

Abstract

AbstractThe close association between inflammation and cancer inspired the synthesis of a series of 1,3,4‐oxadiazole derivatives (compounds H4‐A‐F) of 6‐methoxynaphtalene. The chemical structures of the new compounds were validated utilizing Fourier‐transform infrared, proton nuclear magnetic resonance, and carbon‐13 nuclear magnetic resonance spectroscopic techniques and CHN analysis. Computer‐aided drug design methods were used to predict the compounds biological target, ADMET properties, toxicity, and to evaluate the molecular similarities between the design compounds and erlotinib, a standard epidermal growth factor receptor (EGFR) inhibitor. The antiproliferative effects of the new compounds were evaluated by the 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2H‐tetrazolium bromide assay, cell cycle analysis, apoptosis detection by microscopy, quantitative reverse transcription‐polymerase chain reaction, and immunoblotting, and EGFR enzyme inhibition assay. In silico analysis of the new oxadiazole derivatives indicated that these compounds target EGFR, and that compounds H4‐A, H4‐B, H4‐C, and H4‐E show similar molecular properties to erlotinib. Additionally, the results indicated that none of the synthesized compounds are carcinogenic, and that compounds H4‐A, H4‐C, and H4‐F are nontoxic. Compound H4‐A showed the best‐fit score against EGFR pharmacophore model, however, the in vitro studies indicated that compound H4‐C was the most cytotoxic. Compound H4‐C caused cytotoxicity in HCT‐116 colorectal cancer cells by inducing both apoptosis and necrosis. Furthermore, compounds H4‐D, H4‐C, and H4‐B had potent inhibitory effect on EGFR tyrosine kinase that was comparable to erlotinib. The findings of this inquiry offer a basis for further investigation into the differences between the synthesized compounds and erlotinib. However, additional testing will be needed to assess all of these differences and to identify the most promising compound for further research.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3